Summary for 4OTY
| Entry DOI | 10.2210/pdb4oty/pdb |
| Descriptor | Prostaglandin G/H synthase 2, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total) |
| Functional Keywords | protein-drug complex, oxidoreductase, nsaids, heme, glycosylation, monotopic membrane protein, drug complex, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor |
| Biological source | Mus musculus (mouse) |
| Total number of polymer chains | 2 |
| Total formula weight | 137278.87 |
| Authors | Xu, S.,Windsor, M.A.,Banerjee, S.,Marnett, L.J. (deposition date: 2014-02-14, release date: 2014-02-26, Last modification date: 2024-11-27) |
| Primary citation | Windsor, M.A.,Valk, P.L.,Xu, S.,Banerjee, S.,Marnett, L.J. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg.Med.Chem.Lett., 23:5860-5864, 2013 Cited by PubMed Abstract: Lumiracoxib is a substrate-selective inhibitor of endocannabinoid oxygenation by cyclooxygenase-2 (COX-2). We assayed a series of lumiracoxib derivatives to identify the structural determinants of substrate-selective inhibition. The hydrogen-bonding potential of the substituents at the ortho positions of the aniline ring dictated the potency and substrate selectivity of the inhibitors. The presence of a 5'-methyl group on the phenylacetic acid ring increased the potency of molecules with a single ortho substituent. Des-fluorolumiracoxib (2) was the most potent and selective inhibitor of endocannabinoid oxygenation. The positioning of critical substituents in the binding site was identified from a 2.35Å crystal structure of lumiracoxib bound to COX-2. PubMed: 24060487DOI: 10.1016/j.bmcl.2013.08.097 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.354 Å) |
Structure validation
Download full validation report
